Drug Profile
NN 4201
Alternative Names: NNC 421001Latest Information Update: 18 Feb 2002
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Class
- Mechanism of Action Glycogen phosphorylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 18 Feb 2002 Discontinued-I for Type-2 diabetes mellitus in Denmark (Unknown route)
- 02 May 2000 Phase-I clinical trials for Type-2 diabetes mellitus in Denmark (Unknown route)
- 16 Apr 1999 New profile